Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.79 USD | +0.47% | -3.60% | +4.70% |
May. 22 | Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target | MT |
May. 16 | Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on Bio-Techne Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Bio-Techne Corporation
Citigroup | |
Argus | |
Scotiabank | |
Leerink Partners | |
UBS | |
Baird | |
RBC Capital Markets | |
Deutsche Bank Securities | |
Stephens Inc. | |
Stifel Nicolaus | |
KeyBanc Capital Markets | |
William Blair & Co. | |
SVB Securities LLC | |
Wells Fargo Securities | |
SVB Leerink |
EPS Revisions
- Stock Market
- Equities
- TECH Stock
- Consensus Bio-Techne Corporation